参考文献/References:
[1] Savarese G,Becher PM,Lund LH,et al. Global burden of heart failure:a comprehensive and updated review of epidemiology[J]. Cardiovasc Res,2023,118(17):3272-3287.
[2] Lippi G,Sanchis-Gomar F,Cervellin G. Global epidemiology of atrial fibrillation:an increasing epidemic and public health challenge[J]. Int J Stroke,2021,16(2):217-121.
[3] Patel RB,Reddy VY,Komtebedde J,et al. Atrial fibrillation burden and atrial shunt?therapy in heart?failure with preserved?ejection fraction[J]. JACC Heart Fail,2023,11(10):1351-1362.
[4] Naser JA,Lee E,Scott CG,et al. Prevalence and incidence of diastolic dysfunction in atrial fibrillation:clinical implications [J]. Eur Heart J,2023,44(48):5049-5060.
[5] Redfield MM,Borlaug BA. Heart failure with preserved ejection fraction:a review[J]. Jama,2023,329(10):827-838.
[6] van Gelder IC,Rienstra M,Bunting KV,et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)[J]. Eur Heart J,2024,45(36):3314-3414.
[7] Paulus WJ,Zile MR. From systemic inflammation to myocardial fibrosis[J]. Circulation Research,2021,128(10):1451-1467.
[8] Pugliese NR,Pellicori P,Filidei F,et al. Inflammatory pathways in heart failure with preserved left ventricular ejection fraction:implications for future interventions[J]. Cardiovasc Res,2023,118(18):3536-3555.
[9] Dridi H,Kushnir A,Zalk R,et al. Intracellular calcium leak in heart failure and atrial fibrillation:a unifying mechanism and therapeutic target[J]. Nat Rev Cardiol,2020,17(11):732-747.
[10] Cho DH,Park SM. Epicardial adipose tissue and heart failure,friend or foe?[J]. Diabetes Metab J,2024,48(3):373-384.
[11] van den Berg MP,Mulder BA,Klaassen SHC,et al. Heart failure with preserved ejection fraction,atrial fibrillation,and the role of senile amyloidosis[J]. Eur Heart J,2019,40(16):1287-1293.
[12] Sha R,Baines O,Hayes A,et al. Impact of obesity on atrial fibrillation pathogenesis and treatment options[J]. J Am Heart Assoc,2024,13(1):e032277.
[13] van Veldhuisen SL,Gorter TM,van Woerden G,et al. Bariatric surgery and cardiovascular disease:a systematic review and meta-analysis[J]. Eur Heart J,2022,43(20):1955-1969.
[14] Marx N,Federici M,Schütt K,et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes[J]. Eur Heart J,2023,44(39):4043-4140.
[15] Triposkiadis F,Sarafidis P,Briasoulis A,et al. Hypertensive heart failure[J]. J Clin Med,2023,12(15):5090.
[16] Lee SR,Park CS,Choi EK,et al. Hypertension burden and the risk of new-onset atrial fibrillation:a nationwide population-based study[J]. Hypertension,2021,77(3):919-928.
[17] Habel N,Infeld M,Lustgarten D,et al. The atrial fibrillation and heart failure with preserved ejection fraction "twindemic”—Shared root causes and treatment targets[J]. Heart Rhythm,2024 ,S1547-5271(24)03290-9.
[18] Sanderson JE,Fang F,Lu M,et al. Obstructive sleep apnoea,intermittent hypoxia and heart failure with a preserved ejection fraction[J]. Heart,2021,107(3):190-194.
[19] Rosoff DB,Davey Smith G,Mehta N,et al. Evaluating the relationship between alcohol consumption,tobacco use,and cardiovascular disease:a multivariable Mendelian randomization study[J]. PLoS Med,2020,17(12):e1003410.
[20] Ding N,Shah AM,Blaha MJ,et al. Cigarette smoking,cessation,and risk of heart failure with preserved and reduced ejection fraction[J]. J Am Coll Cardiol,2022,79(23):2298-2305.
[21] Biddinger KJ,Emdin CA,Haas ME,et al. Association of habitual alcohol intake with risk of cardiovascular disease[J]. JAMA Netw Open,2022,5(3):e223849.
[22] Rasoul D,Ajay A,Abdullah A,et al. Alcohol and heart failure[J]. Eur Cardiol,2023,18:e65.
[23] Verhaert DVM,Brunner-La Rocca HP,van Veldhuisen DJ,et al. The bidirectional interaction between atrial fibrillation and heart failure:consequences for the management of both diseases[J]. Europace,2021,23(23 Suppl 2):ii40-ii45.
[24] Rahbar Kouibaran F,Sabatino M,Barozzi C,et al. Atrial natriuretic peptides as a bridge between atrial fibrillation,heart failure,and amyloidosis of the atria[J]. Int J Mol Sci,2023,,24(7):6470.
[25] Vaduganathan M,Piccini JP,Camm A J,et al. Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction:a post-hoc analysis of the ATHENA trial[J]. Eur J Heart Fail,2022,24(6):1094-1101.
[26] Sarzani R,Allevi M,di Pentima C ,et al. Role of cardiac natriuretic peptides in heart structure and function[J]. Int J Mol Sci,2022,23(22):14415.
[27] Deferm S,Bertrand PB,Verbrugge FH,et al. Atrial functional mitral regurgitation:JACC review topic of the week[J]. J Am Coll Cardiol,2019,73(19):2465-2476.
[28] Rattka M,Kühberger A,Pott A,et al. Catheter ablation for atrial fibrillation in HFpEF patients-A propensity-score-matched analysis[J]. J Cardiovasc Electrophysiol,2021,32(9):2357-2367.
[29] Shiraishi Y,Kohsaka S,Ikemura N,et al. Catheter ablation for patients with atrial fibrillation and heart failure with reduced and preserved ejection fraction:insights from the KiCS-AF multicentre cohort study[J]. Europace,2023,25(1):83-91.
[30] von Olshausen G,Benson L,Dahlstr?m U,et al. Catheter ablation for patients with atrial fibrillation and heart failure:insights from the Swedish Heart Failure Registry[J]. Eur J Heart Fail,2022,24(9):1636-1646.
[31] Tsuda T,Kato T,Usuda K,et al. Effect of catheter ablation for atrial fibrillation in heart failure with mid-range or preserved ejection fraction—Pooled analysis of the AF Frontier Ablation Registry and Hokuriku-Plus AF Registry[J]. Circ J,2023,87(7):939-946.
[32] Xie Z,Qi B,Wang Z,et al. Ablation for atrial fibrillation improves the outcomes in patients with heart failure with preserved ejection fraction[J]. Europace,2023,26(1):euad363.
[33] Packer DL,Piccini JP,Monahan KH,et al. Ablation versus drug therapy for atrial fibrillation in heart failure:results from the CABANA Trial[J]. Circulation,2021,143(14):1377-1390.
[34] Parkash R,Wells GA,Rouleau J,et al. Randomized ablation-based rhythm-control versus rate-control trial in patients with heart failure and atrial fibrillation:results from the RAFT-AF trial[J]. Circulation,2022,145(23):1693-1704.
[35] Chieng D,Sugumar H,Segan L,et al. Atrial fibrillation ablation for heart failure with preserved ejection fraction: a randomized controlled trial[J]. JACC Heart Fail,2023,11(6):646-658.
[36] Mahalleh M,Soleimani H,Pazoki M,et al. Heart failure with preserved ejection fraction and atrial fibrillation:catheter ablation vs. standard medical therapy — A systematic review and meta-analysis[J]. Heart Fail Rev,2025,30(1):1-15.
[37] Oraii A,McIntyre WF,Parkash R,et al. Atrial fibrillation ablation in heart failure with reduced vs preserved ejection fraction:a systematic review and meta-analysis[J]. JAMA Cardiol,2024,9(6):545-555.
[38] Sugumar H,Nanayakkara S,Vizi D,et al. A prospective STudy using invAsive haemodynamic measurements foLLowing catheter ablation for AF and early HFpEF:STALL AF-HFpEF[J]. Eur J Heart Fail,2021,23(5):785-796.
[39] Kosiborod MN,Abildstr?m SZ,Borlaug BA,et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity[J]. N Engl J Med,2023,389(12):1069-1084.
[40] Wang Q,Zhuo C,Xia Q,et al. Sacubitril/valsartan can reduce atrial fibrillation recurrence after catheter ablation in patients with persistent atrial fibrillation[J]. Cardiovasc Drugs Ther,2023,37(3):549-560.
[41] Zhang Z,Xiao Y,Dai Y,et al. Device therapy for patients with atrial fibrillation and heart failure with preserved ejection fraction[J]. Heart Fail Rev,2024,29(2):417-430.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(3):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(3):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(3):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(3):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(3):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
[11]唐欣 罗素新.心房颤动合并 射血分数保留的心力衰竭的研究进展[J].心血管病学进展,2019,(5):753.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.022]
TANG Xin,LUO Suxin.Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2019,(3):753.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.022]